Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab

Clin Pharmacol Ther. 2021 Jul;110(1):29-31. doi: 10.1002/cpt.2081. Epub 2020 Nov 4.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Drug Approval / legislation & jurisprudence*
  • Europe
  • Government Agencies
  • Humans
  • Time Factors
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • olaratumab